Researchers from New York, including Susan Sharfstein, PhD, have partnered with DeepSeq.AI to develop an artificial intelligence model predicting the manufacturability of protein-based drugs in Chinese Hamster Ovary (CHO) cells. The project involves screening a large library of single-chain antibodies (VHH) expressed on CHO cell surfaces to assess expression levels. Sequencing of DNA from high-expressing clones will iteratively train the AI for enhanced predictive accuracy across diverse antibody formats. This initiative aims to address a major bottleneck in protein drug production by enabling early identification of candidates likely to express successfully at commercial scale, thus accelerating biologic drug development.